Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2008 (Fiscal Third Quarter)
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which develops and markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 31, 2008 |
Three Months Ended July 31, 2007 |
Nine Months Ended July 31, 2008 |
Nine Months Ended July 31, 2007 |
|---|---|---|---|---|
| Net Sales | $285,884 | $251,862 | $794,367 | $696,817 |
| Gross Profit | $155,097 | $145,924 | $447,986 | $402,291 |
| Gross Margin % | 54% | 58% | 56% | 58% |
| Operating Income | $31,044 | $23,658 | $79,461 | $49,951 |
| Net Income | $17,879 | $8,180 | $35,997 | $13,001 |
| Diluted EPS | $0.39 | $0.18 | $0.79 | $0.29 |
| Operating Cash Flow (9mo) | $55,521 (2008) vs $95,862 (2007) | |||
| Total Debt | $927.8 million (July 31, 2008) | |||
| Cash & Equivalents | $3.4 million (July 31, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% year-over-year for both the quarter and the nine-month period. Growth was driven by CooperVision (up 15%) and CooperSurgical (up 7-9%). Constant currency growth was 8%.
- Profitability: Operating income surged 31% for the quarter and 59% for the nine-month period. Net income increased significantly, with diluted EPS rising from $0.18 to $0.39 for the quarter.
- Margin Compression: Gross margin decreased from 58% to 54% for the quarter, attributed to a shift in product mix toward lower-margin single-use spheres and production start-up costs for new silicone hydrogel products.
- Restructuring Costs: Restructuring costs decreased significantly to $0.2 million for the quarter (from $2.1 million prior year) as the Ocular Sciences integration plan was substantially completed.
- Debt Activity: On July 1, 2008, the Company repurchased all $115 million of its 2.625% Convertible Senior Debentures, resulting in a $3.0 million write-off of unamortized costs.
Outlook, Risks, and Management Commentary
- Product Launches: Management highlights the global launch of Biofinity (silicone hydrogel) and the U.S. launch of Avaira. Future growth depends on the success of these products and the upcoming launch of Biofinity toric in early 2009.
- Capital Expenditures: Fiscal 2008 capital expenditures are expected to be $140-$160 million, primarily for manufacturing capacity expansion. Fiscal 2009 guidance is lowered to $125-$140 million due to yield improvements.
- Legal Proceedings: The Company is defending a securities class action lawsuit regarding the Ocular merger and financial projections. Additionally, a patent infringement lawsuit by Bausch & Lomb regarding Biomedics toric lenses remains pending, though the Company believes it is without merit.
- Tax Rate: The effective tax rate for the nine months ended July 31, 2008, was 16.2%, down from 33.3% in the prior year, primarily due to a favorable shift in the geographic mix of income.
- Liquidity: Cash and cash equivalents are low at $3.4 million. The Company relies on operating cash flow and a $650 million revolving credit facility to fund operations and capital expenditures.
Investor Verification Checklist
- Convertible Debt Repurchase: Verify the impact of the $3.0 million write-off related to the repurchase of the 2.625% Convertible Senior Debentures on interest expense and net income.
- Inventory Levels: Review inventory months-on-hand (6.8 months) and the rationale for building inventory in anticipation of new product launches versus potential obsolescence risks.
- Restructuring Completion: Confirm the status of the Ocular Sciences integration plan and the remaining cash-related restructuring costs (estimated $25-$30 million total).
- Legal Exposure: Assess the potential financial impact of the ongoing securities litigation and the Bausch & Lomb patent dispute.
- Debt Covenants: Review the terms of the $650 million revolving credit facility and the $350 million senior notes to ensure compliance with covenants given the current debt-to-equity ratio of 0.62:1.